Featured Articles

Phototherapy for Psoriasis: A Safe and Effective Treatment Modality

By May 12, 2020May 20th, 2020No Comments

Dermatology News

Featured Article

“Fewer people are doing mainstay full-body phototherapy as in the past, as biologics and other systemic therapies have proven to be safe and much more effective,” Dr. Nestor said in a recent interview with Dermatology Times.

Read Article Now

Phototherapy for Psoriasis: A Safe and Effective Treatment Modality

A study recently published in the JDD reveals phototherapy remains a safe and effective treatment modality for mild to moderate psoriasis vulgaris

Phototherapy remains a safe and effective treatment modality for mild to moderate psoriasis, according to Mark S. Nestor, M.D., Ph.D., in a study recently published in the Journal of Drugs in Dermatology.
Current options for treating psoriasis include systemic and topical agents: systemic treatment options may involve immune inhibitors, and/or immune modulators. For moderate to severe cases, biologic agents may be used.
Topical agents may be comprised of ointments, medicated baths, and phototherapy.

“Fewer people are doing mainstay full-body phototherapy as in the past, as biologics and other systemic therapies have proven to be safe and much more effective,” Dr. Nestor said in a recent interview with Dermatology Times.

“Additionally,” he added, “laser has largely taken over for individual and spot treatment of specific areas because you don’t have the same issue of systemic problems with burning.”

In the study, “Randomized, Investigator-Blinded Study to Compare the Efficacy and Tolerance of a 650-microsecond, 1064-nm YAG Laser to a 308-nm Excimer Laser for the Treatment of Mild to Moderate Psoriasis Vulgaris,” co-authored by Dr. Nestor, Daniel Fischer DO MS,a and David Arnold DOa eligible subjects enrolled in a randomized, investigator-blinded study.

Psoriatic plaques on one side of the body were treated with the 650-microsecond laser and plaques on the other side were treated with the 308-nm excimer laser. Study subjects received up to 15 treatments, twice weekly, or fewer if full clearance was achieved. Efficacy and tolerance were evaluated by the mPASI scores and local skin reactions, respectively.

Both devices showed efficacy in treating psoriatic plaques. Differences between the two devices were not significant for redness, thickness, scaliness, mPASI scores for arms and legs, and overall mPASI scores for the treated psoriatic plaques on each side of the body. The investigator-assessed scores for erosion/ulceration, vesicles, erythema, scaling, edema, and atrophy were low and identical for both sides of the body.

“There is potential for utilizing this therapy much more in the future, especially in areas such as the palms and soles, where excimer appears to be less effective,” Dr. Nestor said.

Read Article Now

You May Also Like

Journal of Drugs in Dermatology JDD featuring GLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease SeverityFeatured ArticlesHairLatest NewsHair Loss Awareness Month
August 7, 2026

Hair Loss Awareness Month

Advancing Hair Loss Solutions As August marks Hair Loss Awareness Month, the Journal of Drugs in Dermatology (JDD) continues to champion evidence-based approaches for practicing dermatologists navigating this challenging field.…
Featured ArticlesLatest NewsPodcastPodcast HighlightsThe JDD Steroid Stewardship Podcast“Please sir, I want some more:” When Rescue Becomes Routine With Prednisone in IBD Care
August 7, 2026

“Please sir, I want some more:” When Rescue Becomes Routine With Prednisone in IBD Care

Guest: Dr. Adelina Hung For decades, corticosteroids have been the gastrointestinal equivalent of duct tape: they fix almost everything, at least long enough to convince us the job is done.…
Journal of Drugs in Dermatology JDD featuring GLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease SeverityFeatured ArticlesGLP-1Latest NewsGLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease Severity
August 6, 2026

GLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease Severity

GLP-1 Receptor Agonists and Psoriasis: The Next Frontier in Metabolic Dermatology? A groundbreaking study published in the Journal of Drugs in Dermatology  highlights a compelling link between metabolic therapy and…

Leave a Reply